<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/422CCC54-2105-4E71-ABB5-0637822E4F9A"><gtr:id>422CCC54-2105-4E71-ABB5-0637822E4F9A</gtr:id><gtr:name>Xavia Technology Limited</gtr:name><gtr:address><gtr:line1>245 CALEDONIAN ROAD</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>N1 1ED</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/422CCC54-2105-4E71-ABB5-0637822E4F9A" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>422CCC54-2105-4E71-ABB5-0637822E4F9A</gtr:id><gtr:name>Xavia Technology Limited</gtr:name><gtr:address><gtr:line1>245 CALEDONIAN ROAD</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>N1 1ED</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>18506.0</gtr:offerGrant><gtr:projectCost>30844.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/00151079-0469-405B-B0DA-4C087EA7B944"><gtr:id>00151079-0469-405B-B0DA-4C087EA7B944</gtr:id><gtr:firstName>Arif</gtr:firstName><gtr:surname>Devji</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=700442"><gtr:id>75EFC4DC-DDF4-4A9A-B6A1-AB58ED2BF1F3</gtr:id><gtr:title>Novel Ink for Security Printing</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Market</gtr:grantCategory><gtr:grantReference>700442</gtr:grantReference><gtr:abstractText>Counterfeit products create an enormous drain on the global economy ? and expose
consumers to dangerous and ineffective products. Total global economic value of counterfeit
products was estimated at $650 billion annually in 2011 and is estimated to lose G20
economies over $125Bn every year in lost tax revenues and higher health costs.
A particular challenge is counterfeit drugs. Federal Drug Administration (FDA) and World
Health Organization (WHO) estimate that 10% of all drugs worldwide are counterfeit - worth
approximately $75Bn per year and putting patients and consumers at significant risk.
Countermeasures taken to authenticate genuine drugs include special packaging measures (eg:
holograms), tamper-proof labels and serial numbering. We believe we can significantly
improve product authentication by formulating a highly secure digital ink for printing variable
data such as serial numbers. This novel ink will reveal extra luminescent information within
printed characters when exposed to Infrared (IR) laser light.
We believe our disruptive new approach leapfrogs current state-of-the-art printed security
measures, improving product authentication, security, reliability and safety by large margins.
This is a platform technology with market applications from printing bank notes, passports
and Tax Stamps to anti-counterfeit packaging for pharmaceuticals and high-end luxury goods.
This market assessment study seeks to identify an optimal market entry point for our secure
ink by consulting stakeholders and key influencers in the anti-counterfeit measures industry
directly to assess their willingness to adopt a new approach. If successful, it will introduce a
new solution into a global anti-counterfeit packaging market worth US$79.3Bn in 2014.

The forecast has been updated correctly now and been re-submitted (29th Jan 2015)</gtr:abstractText><gtr:fund><gtr:end>2015-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>18506</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">700442</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>